Circassia Pharmaceuticals plc provided revenue guidance for the year ended December 31, 2018 and reaffirmed sales guidance for the year ending December 2019. For the year ended December 31, 2018, the company expects revenue to be in the range £48 million to £52 million,, following higher Tudorza® rebates in federal channels during the second half of 2018 and delayed recognition of revenue in China due to the establishment of the company's new local subsidiary and supply chain. The Board's expectations for 2019 remain unchanged with significant opportunities for strong sales growth in the current financial year to December 2019 following exercise of the Tudorza option and establishment of the direct sales operation in China.